Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis

Waning immunity after two SARS-CoV-2 mRNA vaccinations and the emergence of variants precipitated the need for a third dose of vaccine. We evaluated early safety and immunogenicity after a third mRNA vaccination in adults who received the mRNA-1273 primary series in the Phase 1 trial approximately 9...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Evan, Jackson, Lisa, Rouphael, Nadine, Widge, Alicia, Montefiori, David, Doria-Rose, Nicole, Suthar, Mehul, Cohen, Kristen, O’Connell, Sarah, Makowski, Mat, Makhene, Mamodikoe, Buchanan, Wendy, Spearman, Paul, Creech, C. Buddy, O’Dell, Sijy, Schmidt, Stephen, Leav, Brett, Bennett, Hamilton, Pajon, Rolando, Posavad, Christine, Hural, John, Beigel, John, Albert, Jim, Abebe, Kuleni, Eaton, Amanda, Rostad, Christina, Rebolledo, Paulina, Kamidani, Satoshi, Graciaa, Daniel, Coler, Rhea, McDermott, Adrian, Ledgerwood, Julie, Mascola, John, DeRosa, Stephen, Neuzil, Kathleen, McElrath, M. Juliana, Roberts, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094107/
https://www.ncbi.nlm.nih.gov/pubmed/35547849
http://dx.doi.org/10.21203/rs.3.rs-1222037/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094107/
https://www.ncbi.nlm.nih.gov/pubmed/35547849
http://dx.doi.org/10.21203/rs.3.rs-1222037/v1

Ejemplares similares